Valuation dashboard for Legend Biotech Corporation (LEGN) with P/E N/A, P/B 3.29, EV/EBITDA 1,753.70 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Analysis Summary
Legend Biotech Corporation reported revenue of $1.03B in the most recent fiscal year, growing at a 5-year CAGR of 68.8%.
Trailing-twelve-month margins: gross margin 56.6%, operating margin -4.4%, net margin -7.2%.
At $21.63 (closing price, October 30, 2026), LEGN has negative trailing earnings (P/E not meaningful) and an ROE of -8.70%. Market capitalisation stands at $4.0B.
Balance sheet quality for LEGN: current ratio of 2.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.29 |
| EV / EBITDA | 1,753.70 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-2,058.58 |
| vs Current Price | -9,617.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $4.0B | 3.29 | -8.7% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $141.7B | 32.53 | 7.01 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $95.5B | 20.50 | 2.82 | 15.1% |
| MRNA | Moderna, Inc. | $88.5B | 12.99 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $56.1B | 42.44 | 6.73 | 16.9% |
| 0QNO.L | Lonza Group AG | CHF 43.8B | 5.43 | -1.3% |
Price
| Price | $21.63 (closing price, October 30, 2026) |
| Market Cap | $4.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -8.70% |
| Return on Invested Capital | -3.71% |
| Return on Assets | -5.23% |
| Gross Margin | 56.58% |
| Operating Margin | -4.42% |
| Net Margin | -7.21% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of LEGN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks